180 related articles for article (PubMed ID: 37822941)
1. A novel bispecific antibody dual-targeting approach for enhanced neutralization against fast-evolving SARS-CoV-2 variants.
Kim JW; Kim HJ; Heo K; Lee Y; Jang HJ; Lee HY; Park JW; Cho YB; Lee JH; Shin HG; Yang HR; Choi HL; Shim HB; Lee S
Front Immunol; 2023; 14():1271508. PubMed ID: 37822941
[TBL] [Abstract][Full Text] [Related]
2. Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants.
Kim JW; Heo K; Kim HJ; Yoo Y; Cho HS; Jang HJ; Lee HY; Ko IY; Woo JR; Cho YB; Lee JH; Yang HR; Shin HG; Choi HL; Hwang K; Kim S; Kim H; Chun K; Lee S
Antiviral Res; 2023 Apr; 212():105576. PubMed ID: 36870394
[TBL] [Abstract][Full Text] [Related]
3. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P
J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510
[TBL] [Abstract][Full Text] [Related]
4. A dual-targeting approach using a human bispecific antibody against the receptor-binding domain of the Middle East Respiratory Syndrome Coronavirus.
Lee JH; Kim JW; Lee HE; Song JY; Cho AH; Hwang JH; Heo K; Lee S
Virus Res; 2024 Jul; 345():199383. PubMed ID: 38697296
[TBL] [Abstract][Full Text] [Related]
5. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
6. Development and Characterization of Phage-Display-Derived Novel Human Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2.
Kim JW; Min SW; Lee J; Shin HG; Choi HL; Yang HR; Lee JH; Cho YB; Shim H; Lee S
Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36552031
[TBL] [Abstract][Full Text] [Related]
7. Empowering SARS-CoV-2 variant neutralization with a bifunctional antibody engineered with tandem heptad repeat 2 peptides.
Kim JW; Lee JH; Kim HJ; Heo K; Lee Y; Jang HJ; Lee HY; Park JW; Cho YB; Shin HG; Yang HR; Lee HE; Song JY; Lee S
J Med Virol; 2024 Mar; 96(3):e29506. PubMed ID: 38445718
[TBL] [Abstract][Full Text] [Related]
8. An Engineered IgG-VHH Bispecific Antibody against SARS-CoV-2 and Its Variants.
Chi H; Wang L; Liu C; Cheng X; Zheng H; Lv L; Tan Y; Zhang N; Zhao S; Wu M; Luo D; Qiu H; Feng R; Fu W; Zhang J; Xiong X; Zhang Y; Zu S; Chen Q; Ye Q; Yan X; Hu Y; Zhang Z; Yan R; Yin J; Lei P; Wang W; Lang G; Shao J; Deng Y; Wang X; Qin C
Small Methods; 2022 Dec; 6(12):e2200932. PubMed ID: 36300882
[TBL] [Abstract][Full Text] [Related]
9. IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern.
Chang MR; Tomasovic L; Kuzmina NA; Ronk AJ; Byrne PO; Johnson R; Storm N; Olmedillas E; Hou YJ; Schäfer A; Leist SR; Tse LV; Ke H; Coherd C; Nguyen K; Kamkaew M; Honko A; Zhu Q; Alter G; Saphire EO; McLellan JS; Griffiths A; Baric RS; Bukreyev A; Marasco WA
Nat Commun; 2022 Oct; 13(1):5814. PubMed ID: 36192374
[TBL] [Abstract][Full Text] [Related]
10. Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern.
Cho H; Gonzales-Wartz KK; Huang D; Yuan M; Peterson M; Liang J; Beutler N; Torres JL; Cong Y; Postnikova E; Bangaru S; Talana CA; Shi W; Yang ES; Zhang Y; Leung K; Wang L; Peng L; Skinner J; Li S; Wu NC; Liu H; Dacon C; Moyer T; Cohen M; Zhao M; Lee FE; Weinberg RS; Douagi I; Gross R; Schmaljohn C; Pegu A; Mascola JR; Holbrook M; Nemazee D; Rogers TF; Ward AB; Wilson IA; Crompton PD; Tan J
Sci Transl Med; 2021 Oct; 13(616):eabj5413. PubMed ID: 34519517
[TBL] [Abstract][Full Text] [Related]
11. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
12. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
Elife; 2022 Aug; 11():. PubMed ID: 36004719
[TBL] [Abstract][Full Text] [Related]
13. Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain.
Gao X; Fan L; Zheng B; Li H; Wang J; Zhang L; Li J; Zhu F
Hum Vaccin Immunother; 2022 Nov; 18(5):2055373. PubMed ID: 35417303
[TBL] [Abstract][Full Text] [Related]
14. Antibody cocktail effective against variants of SARS-CoV-2.
Liang KH; Chiang PY; Ko SH; Chou YC; Lu RM; Lin HT; Chen WY; Lin YL; Tao MH; Jan JT; Wu HC
J Biomed Sci; 2021 Nov; 28(1):80. PubMed ID: 34814920
[TBL] [Abstract][Full Text] [Related]
15. Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617.
Peng L; Hu Y; Mankowski MC; Ren P; Chen RE; Wei J; Zhao M; Li T; Tripler T; Ye L; Chow RD; Fang Z; Wu C; Dong MB; Cook M; Wang G; Clark P; Nelson B; Klein D; Sutton R; Diamond MS; Wilen CB; Xiong Y; Chen S
Nat Commun; 2022 Mar; 13(1):1638. PubMed ID: 35347138
[TBL] [Abstract][Full Text] [Related]
16. Correlation of the Commercial Anti-SARS-CoV-2 Receptor Binding Domain Antibody Test with the Chemiluminescent Reduction Neutralizing Test and Possible Detection of Antibodies to Emerging Variants.
Morinaga Y; Tani H; Terasaki Y; Nomura S; Kawasuji H; Shimada T; Igarashi E; Saga Y; Yoshida Y; Yasukochi R; Kaneda M; Murai Y; Ueno A; Miyajima Y; Fukui Y; Nagaoka K; Ono C; Matsuura Y; Fujimura T; Ishida Y; Oishi K; Yamamoto Y
Microbiol Spectr; 2021 Dec; 9(3):e0056021. PubMed ID: 34851163
[TBL] [Abstract][Full Text] [Related]
17. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
18. A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations.
Bertoglio F; Fühner V; Ruschig M; Heine PA; Abassi L; Klünemann T; Rand U; Meier D; Langreder N; Steinke S; Ballmann R; Schneider KT; Roth KDR; Kuhn P; Riese P; Schäckermann D; Korn J; Koch A; Chaudhry MZ; Eschke K; Kim Y; Zock-Emmenthal S; Becker M; Scholz M; Moreira GMSG; Wenzel EV; Russo G; Garritsen HSP; Casu S; Gerstner A; Roth G; Adler J; Trimpert J; Hermann A; Schirrmann T; Dübel S; Frenzel A; Van den Heuvel J; Čičin-Šain L; Schubert M; Hust M
Cell Rep; 2021 Jul; 36(4):109433. PubMed ID: 34273271
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity.
Jensen JL; Sankhala RS; Dussupt V; Bai H; Hajduczki A; Lal KG; Chang WC; Martinez EJ; Peterson CE; Golub ES; Rees PA; Mendez-Rivera L; Zemil M; Kavusak E; Mayer SV; Wieczorek L; Kannan S; Doranz BJ; Davidson E; Yang ES; Zhang Y; Chen M; Choe M; Wang L; Gromowski GD; Koup RA; Michael NL; Polonis VR; Rolland M; Modjarrad K; Krebs SJ; Joyce MG
J Virol; 2023 Jul; 97(7):e0159622. PubMed ID: 37395646
[TBL] [Abstract][Full Text] [Related]
20. Broad Sarbecovirus Neutralizing Antibodies Obtained by Computational Design and Synthetic Library Screening.
Yang X; Duan H; Liu X; Zhang X; Pan S; Zhang F; Gao P; Liu B; Yang J; Chi X; Yang W
J Virol; 2023 Jul; 97(7):e0061023. PubMed ID: 37367229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
